TOP TEN perturbations for NM_000358 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000358
Selected probe(set): 201506_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000358 (201506_at) across 5392 perturbations tested by GENEVESTIGATOR:

TC-71 / TC-32

Relative Expression (log2-ratio):-6.969451
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing?s sarcoma. Synonyms:TC32 Cellosaurus code:

OVCAR-8 RIIB / OVCAR-8

Relative Expression (log2-ratio):-6.28288
Number of Samples:3 / 3
Experimental OVCAR-8 RIIB
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Stably transfected with the cAMP-dependent protein kinase (PKA) regulatory subunit gene for RII?. Parental cell line:: OVCAR-8 Cellosaurus code:
Control OVCAR-8
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Synonyms:NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8 Cellosaurus code:

VTX-2337 study 1 / 3M-055 study 1

Relative Expression (log2-ratio):-6.1303654
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control 3M-055 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist.

stem cell differentiation study 41 (T3pi) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):6.1297703
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

VTX-2337 study 1 / untreated monocyte sample

Relative Expression (log2-ratio):-6.1245193
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control untreated monocyte sample
Peripheral blood monocytes isolated from healthy donors.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-6.1082096
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

OVCAR-8 RIA / OVCAR-8

Relative Expression (log2-ratio):-6.0066214
Number of Samples:3 / 3
Experimental OVCAR-8 RIA
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Stably transfected with the cAMP-dependent protein kinase (PKA) regulatory subunit gene for RI?. Parental cell line:: OVCAR-8 Cellosaurus code:
Control OVCAR-8
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Synonyms:NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8 Cellosaurus code:

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):5.7717
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):5.670336
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

colorectal cancer study 33 (carcinoma; colonic crypt) / normal colonic crypt epithelial cell sample

Relative Expression (log2-ratio):5.4364634
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control normal colonic crypt epithelial cell sample
Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.